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Abstract
Background:  Tuberous sclerosis complex (TSC) is an autosomal dominant disorder. It is
characterized by seizures, mental retardation and hamartomatous lesions, including facial
angiofibroma, subependymal giant cell astrocytoma, cardiac rhabdomyoma and renal
angiomyolipoma (AML). AMLs can bleed severely in the retroperitoneal space.
Case presentation: Herein, we present the case of a TSC patient presenting with recurrent
severe episodes of retroperitoneal hemorrhage from AMLs successfully managed by angio-
embolization.
Conclusion: Transarterial embolization is effective in preventing and controlling hemorrhage in
patients with AMLs of the kidney
Background
Tuberous sclerosis complex (TSC) or Bourneville's disease
is a rare genetic disorder, either sporadic or inherited by
an autosomal dominant transmission. Mutations in one
of two genes, TSC1 and TSC2, have been identified as
causes of TSC. Affected patients develop hamartomatous
lesions in different organs, most commonly in the brain,
eyes, heart, kidney, skin and lungs. Angiomyolipomas
(AML) of the kidney are the most common TSC lesion,
occurring in 70 to 80% of adults and older children.[1]
These lesions can be a bleeding source.
Case presentation
In September 2000, a 48 year-old Caucasian male with
sporadic tuberous sclerosis presented to the emergency
room with acute right flank pain, large abdominal mass,
signs and symptoms of internal bleeding (hypotension,
tachycardia and acute anemia). Abdominal CT scan
showed bilateral renal giant angiomyolipomatosis with a
honey-comb aspect of the kidneys and a right retroperito-
neal haematoma. Moreover, an arterial contrast blush was
seen within the right retroperitoneal hemorrhagic infarc-
tion (Figure 1). The patient underwent angiography (Fig-
ure 2), which showed the right kidney to be supplied by
two main arteries and the presence of multiple intraparen-
chymal aneurysms (arrows) in the territory of the lower
artery. There was no active bleeding but due to the size of
AML and of the aneurysms a selective embolization with
metal coils was carried out. Adjunctive features of the syn-
drome in this patient included sebaceous adenoma of the
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face (Figure 3), and sub-ependymal calcifications (Figure
4). The course was uneventful and kidney function was
maintained. A further episode of massive retroperitoneal
bleeding occurred 40 months later. The bleeding source
was from a AML lesion of the upper pole of the left kidney
(Figure 5). Control was achieved by selective angio-
embolization. Since then, there has been no recurrence of
retroperitoneal bleeding, but the patient has developed a
mild renal failure.
CT scan showing honeycomb kidneys (white arrows) with  contrast blush inside a right retroperitoneal hematoma (black  arrow) Figure 1
CT scan showing honeycomb kidneys (white arrows) 
with contrast blush inside a right retroperitoneal 
hematoma (black arrow).
selective angiography of the right kidney showing giant angi- omyolipomas before embolization Figure 2
selective angiography of the right kidney showing 
giant angiomyolipomas before embolization.
sebaceous adenomas of the face Figure 3
sebaceous adenomas of the face.
subependymal calcification as seen at the CT scan Figure 4
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Discussion
The three major renal manifestations of TSC include AML
and less frequently polycystic kidney disease (PKD) and
renal cell carcinoma (RCC), arising alone or in combina-
tion. Of these, however, only AML are a major criterion
for TSC diagnosis because neither the presence of cysts nor
RCC is sufficiently specific for TSC. Angiomyolipomas are
benign tumors composed of abnormal vessels, immature
smooth muscle cells and fat cells. Their incidence in the
general population is 1–2%, whereas in patients with TSC
the incidence of AML has been estimated at 50–80%. In
respect to sporadic AML, patients with TSC significantly
have multiple and bilateral AML that tend to grow with
time. As AML grow, aneurysms develop inside the mass.
Bleeding from ruptured aneurysm increases in frequency
when tumors become larger than 4 cm. Giant renal AML
in Bourneville's syndrome raise a surgical interest because
they are a source of life-threatening hemorrhage. Hemor-
rhage from AML has been reported among the most com-
mon causes of death in patients with TSC.[2]
Management of AML greater than 4 cm electively identi-
fied by imaging series should be balanced between the
need to prevent life-threatening bleeding and the issue of
preserve as much functional renal parenchyma as possi-
ble. For this purpose a variety of methods have been pro-
posed. These include selective renal angiography and
embolization, AML ablation by cryotherapy or radiofre-
quency and partial nephrectomy.[2,3] In the presence of
ongoing bleeding, selective renal embolization is a safe
and effective method to achieve hemorrhage control and
to reduce the size of AML. This treatment is minimally
invasive and preserves renal function. Currently, emboli-
zation is proposed as the first choice of intervention for
symptomatic AMLs or to prevent hemorrhage when AMLs
exceed 4 cm in diameter.[4,5] Patients with TSC have
however a 40% recurrence rate of symptomatic AMLs with
a median time interval from embolization to recurrence
of approximately 79 months.[6] As genes mutations in
TSC result in activation of the mammalian target of
rapamycin (mTOR), therapy with sirolimus, a suppressor
of the mTOR signaling, has been recently implemented in
order to reduce the size of AML and to prevent retroperi-
toneal bleeding.[7] As result of the treatment, AMLs
regressed during the therapy but increased again once the
therapy was stopped. Some severe adverse events from
sirolimus also were reported. Thus, so far, the role of
mTOR suppressors in preventing hemorrhage from AML
seems to be very promising, but yet, it cannot be consid-
ered as standard of care. Most of TSC patients presenting
with recurrence and of re-bleeding may be first safety and
effectively managed by redo angio-embolization. How-
ever some patients with repetitive renal bleeding will
eventually require a nephrectomy. For these cases com-
bined nephrectomy and pre-emptive renal transplanta-
tion may be the procedure of choice, as it removes the risk
of severe bleeding and represents definitive treatment.[8]
Conclusion
Transarterial embolization is effective in preventing and
controlling hemorrhage in patients with AMLs of the kid-
ney. When AMLs are associated to TSC, recurrence of
bleeding is not uncommon and redo angio-embolization
may be required.
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